We are analyzing https://link.springer.com/article/10.1007/s12032-019-1307-8.

Title:
Circulating CD16+CD56+ nature killer cells indicate the prognosis of colorectal cancer after initial chemotherapy | Medical Oncology
Description:
As the prognosis of colorectal cancer (CRC) does not always coincide with the pathology and/or surgical findings, a reliable noninvasive prediction tool for the prognosis of CRC is needed. Patients admitted for initial treatment of CRC between January 1, 2015 and December 31, 2015 were retrieved and reviewed. Records of circulating CD16+ CD56+ natural killer (NK) cells were analyzed before and after the initial chemotherapy of FOLFOX plan. Patients were followed up until June 30, 2019. One hundred and twenty-four cases after the FOLFOX chemotherapy were enrolled into this study. There were no significant differences in gender, age, or number of metastasis cases between the survival group and the nonsurvival group (p > 0.05), but significant differences in pre-chemotherapy, post-chemotherapy, and the differences between pre- and post-chemotherapy circulating CD16+ CD56+ NK cells between the survival group and the nonsurvival group (p < 0.01, p < 0.01, and p < 0.05, respectively) were observed. For the prediction of survival and nonsurvival CRC cases, the Areas Under the Curve were 0.626 and 0.759 in the Receiver-Operating Characteristic curves for the pre- and post-chemotherapy circulating CD16+ CD56+NK cells, respectively. Using an optimal cutoff value of 11.8% in post-chemotherapy circulating CD16+CD56+NK cells to differentiate survival and nonsurvival cases, the odds ratio was 0.12 (0.05, 0.27), p < 0.001. The percentages of both pre-chemotherapy and post-chemotherapy circulating CD16+CD56+NK cells were negatively correlated with the prognosis of CRC. The percentage of post-chemotherapy circulating CD16+CD56+NK cells was able to effectively predict the prognosis of CRC cases.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

article, google, scholar, cancer, colorectal, cells, cas, killer, patients, circulating, pubmed, prognosis, natural, nature, cell, immunol, crc, postchemotherapy, access, dis, markers, privacy, cookies, content, data, oncology, sun, cases, survival, group, human, wang, central, information, publish, search, initial, chemotherapy, number, cui, nonsurvival, clinical, colon, author, oncol, prognostic, rev, med, peripheral, blood,

Topics {✒️}

circulating cd16+ cd56+ natural killer month download article/chapter early-stage colorectal cancer” receiver-operating characteristic curves high neutrophil-lymphocyte ratio natural killer cells gene expression-based study nkt cell subsets di qu & ruya sun tumorassociated nk cells peripheral nk cells cells predict outcome nkt cells harbin medical university progenitor cells occurs activating killer immunoglobulin full article pdf privacy choices/manage cookies related subjects kejun nan metastatic colorectal cancer colorectal cancer compared post-chemotherapy increased cancer risk personal data colon cancer receptor-mediated stimulation global cancer statistics blood biochemical test lymph node size data protection cancer immunol immunother colorectal cancer patients european economic area low-dose chemoradiotherapy de vries nl preoperative tim-3 expression peptide-mhc class matrix metalloproteinase-1 polymorphism common genes refers 1h-nmr spectrometry jiao tong university yanta west road ethics declarations conflict article cui retrieved lymph nodes conditions privacy policy immune cells ca cancer circulating t

Questions {❓}

KIR and disease: a model system or system of models?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Circulating CD16+CD56+ nature killer cells indicate the prognosis of colorectal cancer after initial chemotherapy
         description:As the prognosis of colorectal cancer (CRC) does not always coincide with the pathology and/or surgical findings, a reliable noninvasive prediction tool for the prognosis of CRC is needed. Patients admitted for initial treatment of CRC between January 1, 2015 and December 31, 2015 were retrieved and reviewed. Records of circulating CD16+ CD56+ natural killer (NK) cells were analyzed before and after the initial chemotherapy of FOLFOX plan. Patients were followed up until June 30, 2019. One hundred and twenty-four cases after the FOLFOX chemotherapy were enrolled into this study. There were no significant differences in gender, age, or number of metastasis cases between the survival group and the nonsurvival group (p > 0.05), but significant differences in pre-chemotherapy, post-chemotherapy, and the differences between pre- and post-chemotherapy circulating CD16+ CD56+ NK cells between the survival group and the nonsurvival group (p < 0.01, p < 0.01, and p < 0.05, respectively) were observed. For the prediction of survival and nonsurvival CRC cases, the Areas Under the Curve were 0.626 and 0.759 in the Receiver-Operating Characteristic curves for the pre- and post-chemotherapy circulating CD16+ CD56+NK cells, respectively. Using an optimal cutoff value of 11.8% in post-chemotherapy circulating CD16+CD56+NK cells to differentiate survival and nonsurvival cases, the odds ratio was 0.12 (0.05, 0.27), p < 0.001. The percentages of both pre-chemotherapy and post-chemotherapy circulating CD16+CD56+NK cells were negatively correlated with the prognosis of CRC. The percentage of post-chemotherapy circulating CD16+CD56+NK cells was able to effectively predict the prognosis of CRC cases.
         datePublished:2019-09-06T00:00:00Z
         dateModified:2019-09-06T00:00:00Z
         pageStart:1
         pageEnd:6
         sameAs:https://doi.org/10.1007/s12032-019-1307-8
         keywords:
            Colorectal cancer
            Nature killer cells
            Prognosis
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-019-1307-8/MediaObjects/12032_2019_1307_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-019-1307-8/MediaObjects/12032_2019_1307_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-019-1307-8/MediaObjects/12032_2019_1307_Fig3_HTML.png
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:36
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Feng Cui
               url:http://orcid.org/0000-0001-8480-0467
               affiliation:
                     name:The First Affiliated Hospital of Xi’an Jiao Tong University
                     address:
                        name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
                        type:PostalAddress
                     type:Organization
                     name:The Second Affiliated Hospital of Harbin Medical University
                     address:
                        name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Di Qu
               affiliation:
                     name:The Second Affiliated Hospital of Harbin Medical University
                     address:
                        name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ruya Sun
               affiliation:
                     name:The Second Affiliated Hospital of Harbin Medical University
                     address:
                        name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kejun Nan
               url:http://orcid.org/0000-0002-9068-7488
               affiliation:
                     name:The First Affiliated Hospital of Xi’an Jiao Tong University
                     address:
                        name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Circulating CD16+CD56+ nature killer cells indicate the prognosis of colorectal cancer after initial chemotherapy
      description:As the prognosis of colorectal cancer (CRC) does not always coincide with the pathology and/or surgical findings, a reliable noninvasive prediction tool for the prognosis of CRC is needed. Patients admitted for initial treatment of CRC between January 1, 2015 and December 31, 2015 were retrieved and reviewed. Records of circulating CD16+ CD56+ natural killer (NK) cells were analyzed before and after the initial chemotherapy of FOLFOX plan. Patients were followed up until June 30, 2019. One hundred and twenty-four cases after the FOLFOX chemotherapy were enrolled into this study. There were no significant differences in gender, age, or number of metastasis cases between the survival group and the nonsurvival group (p > 0.05), but significant differences in pre-chemotherapy, post-chemotherapy, and the differences between pre- and post-chemotherapy circulating CD16+ CD56+ NK cells between the survival group and the nonsurvival group (p < 0.01, p < 0.01, and p < 0.05, respectively) were observed. For the prediction of survival and nonsurvival CRC cases, the Areas Under the Curve were 0.626 and 0.759 in the Receiver-Operating Characteristic curves for the pre- and post-chemotherapy circulating CD16+ CD56+NK cells, respectively. Using an optimal cutoff value of 11.8% in post-chemotherapy circulating CD16+CD56+NK cells to differentiate survival and nonsurvival cases, the odds ratio was 0.12 (0.05, 0.27), p < 0.001. The percentages of both pre-chemotherapy and post-chemotherapy circulating CD16+CD56+NK cells were negatively correlated with the prognosis of CRC. The percentage of post-chemotherapy circulating CD16+CD56+NK cells was able to effectively predict the prognosis of CRC cases.
      datePublished:2019-09-06T00:00:00Z
      dateModified:2019-09-06T00:00:00Z
      pageStart:1
      pageEnd:6
      sameAs:https://doi.org/10.1007/s12032-019-1307-8
      keywords:
         Colorectal cancer
         Nature killer cells
         Prognosis
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-019-1307-8/MediaObjects/12032_2019_1307_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-019-1307-8/MediaObjects/12032_2019_1307_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-019-1307-8/MediaObjects/12032_2019_1307_Fig3_HTML.png
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:36
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Feng Cui
            url:http://orcid.org/0000-0001-8480-0467
            affiliation:
                  name:The First Affiliated Hospital of Xi’an Jiao Tong University
                  address:
                     name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
                     type:PostalAddress
                  type:Organization
                  name:The Second Affiliated Hospital of Harbin Medical University
                  address:
                     name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Di Qu
            affiliation:
                  name:The Second Affiliated Hospital of Harbin Medical University
                  address:
                     name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ruya Sun
            affiliation:
                  name:The Second Affiliated Hospital of Harbin Medical University
                  address:
                     name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kejun Nan
            url:http://orcid.org/0000-0002-9068-7488
            affiliation:
                  name:The First Affiliated Hospital of Xi’an Jiao Tong University
                  address:
                     name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:36
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The First Affiliated Hospital of Xi’an Jiao Tong University
      address:
         name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
         type:PostalAddress
      name:The Second Affiliated Hospital of Harbin Medical University
      address:
         name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
         type:PostalAddress
      name:The Second Affiliated Hospital of Harbin Medical University
      address:
         name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
         type:PostalAddress
      name:The Second Affiliated Hospital of Harbin Medical University
      address:
         name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
         type:PostalAddress
      name:The First Affiliated Hospital of Xi’an Jiao Tong University
      address:
         name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Feng Cui
      url:http://orcid.org/0000-0001-8480-0467
      affiliation:
            name:The First Affiliated Hospital of Xi’an Jiao Tong University
            address:
               name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
               type:PostalAddress
            type:Organization
            name:The Second Affiliated Hospital of Harbin Medical University
            address:
               name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Di Qu
      affiliation:
            name:The Second Affiliated Hospital of Harbin Medical University
            address:
               name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Ruya Sun
      affiliation:
            name:The Second Affiliated Hospital of Harbin Medical University
            address:
               name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
               type:PostalAddress
            type:Organization
      name:Kejun Nan
      url:http://orcid.org/0000-0002-9068-7488
      affiliation:
            name:The First Affiliated Hospital of Xi’an Jiao Tong University
            address:
               name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
      name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
      name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
      name:Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
      name:Department of Oncology, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(1)

https://link.springer.com/article/10.1007/s12032-019-1307-8/mailto:[email protected]

External Links {🔗}(105)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.23s.

LINK . SPRINGER . COM {}